View Older Stories View More Recent Stories

Jan 21, 2021 12:00PM Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
Jan 19, 2021 04:15PM Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
Jan 12, 2021 05:45PM Regeneron (REGN) Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
Jan 12, 2021 05:45PM Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
Dec 29, 2020 04:30PM Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
Dec 17, 2020 05:03PM Regeneron (REGN) Reports Publication of Initial Clinical Data from Ongoing Ph. 1/2/3 Trial of Antibody Cocktail Casirivimab & Imdevimab in Non-Hospitalized Patients with COVID-19
Dec 17, 2020 05:00PM New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
Dec 16, 2020 07:00AM Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Dec 5, 2020 05:00PM Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
Nov 30, 2020 07:00AM Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
Nov 30, 2020 01:00AM Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Nov 30, 2020 12:59AM Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Nov 23, 2020 06:07AM Regeneron's (REGN) COVID-19 Antibody Cocktail REGEN-COV2 Receive FDA Emergency Use Authorization
Nov 21, 2020 07:56PM Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
Nov 16, 2020 07:00AM Regeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year
Nov 13, 2020 04:15PM Regeneron Announces Investor Conference Presentations
Nov 5, 2020 06:30AM Regeneron Reports Third Quarter 2020 Financial and Operating Results
Oct 30, 2020 09:13AM Regeneron (REGN) Says REGN-COV2 IDMC Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
Oct 30, 2020 09:12AM REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Require
Oct 29, 2020 02:32PM Regeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
Oct 29, 2020 07:57AM Regeneron (REGN) Announces FDA Accepts for Priority Review Libtayo for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Oct 29, 2020 07:00AM FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Oct 28, 2020 05:09PM Regeneron (REGN) Said Results Shows REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
Oct 28, 2020 05:00PM Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
Oct 27, 2020 04:30PM Regeneron Announces Investor Conference Presentations
Oct 26, 2020 08:00AM Regeneron (REGN) Announces Dupixent Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for First Time at Scientific Meetings
Oct 26, 2020 08:00AM Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
Oct 26, 2020 07:59AM Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
Oct 16, 2020 08:00AM CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
Oct 16, 2020 07:59AM Regeneron (REGN) Announces CHMP Recommends Approval of Dupixent for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Oct 16, 2020 07:59AM CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Oct 14, 2020 05:42PM Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)
Oct 13, 2020 05:56AM Regeneron (REGN) Reports Pivotal Ph. 3 Trial of Dupixent (dupilumab) Met Primary & All Key Secondary Endpoints, Significantly Reducing Severe Asthma Attacks in Children
Oct 13, 2020 01:00AM Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
Oct 13, 2020 12:59AM Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial
Oct 9, 2020 04:50PM U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment
Oct 8, 2020 12:38PM Fauci says 'reasonably good chance' Regeneron antibody therapy helped Trump
Oct 8, 2020 01:09AM Trump eyes return to rallies Saturday after doctor says COVID-19 therapy completed
Oct 7, 2020 12:06AM Trump says catching COVID-19 was 'blessing from God'
Oct 6, 2020 04:05PM Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020
Sep 29, 2020 04:02PM Regeneron (REGN) REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Sep 29, 2020 04:01PM Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Sep 21, 2020 08:27AM Regeneron (REGN), Sanofi (SNY) Announce Late-breaking ESMO Presentation Shows Libtayo Monotherapy Increases OS in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Sep 21, 2020 08:25AM Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Sep 21, 2020 08:25AM Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Sep 20, 2020 08:25PM Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Sep 18, 2020 06:07AM Regeneron (REGN) Positive Pivotal Data for Libtayo Monotherapy in Locally Advanced BCC Featured as Late-breaking Presentation at ESMO
Sep 18, 2020 03:05AM Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
Sep 18, 2020 03:05AM Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
Sep 14, 2020 07:05AM Regeneron (REGN) Reports RECOVERY COVID-19 Phase 3 Trial to Evaluate REGN-COV2 Investigational Antibody Cocktail in UK
View More Recent Stories View Older Stories